Ownership Action to Note: Tetralogic Pharmaceuticals Corp (OTCMKTS:TLOG) Institutional Investor Sentiment Is 0.27

November 16, 2016 - By Nellie Frank   ·   0 Comments

Ownership Action to Note: Tetralogic Pharmaceuticals Corp (OTCMKTS:TLOG) Institutional Investor Sentiment Is 0.27

Sentiment for Tetralogic Pharmaceuticals Corp (OTCMKTS:TLOG)

Tetralogic Pharmaceuticals Corp (OTCMKTS:TLOG) institutional sentiment decreased to 0.27 in Q2 2016. Its down -0.36, from 0.63 in 2016Q1. The ratio dropped, as 3 investment managers increased or opened new stock positions, while 11 reduced and sold their stock positions in Tetralogic Pharmaceuticals Corp. The investment managers in our partner’s database now possess: 660,364 shares, down from 862,305 shares in 2016Q1. Also, the number of investment managers holding Tetralogic Pharmaceuticals Corp in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 7 Reduced: 4 Increased: 2 New Position: 1.

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The company has a market cap of $1.24 million. The Firm is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. It currently has negative earnings. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases.

The stock closed at $0.05 during the last session. It is down 76.74% since April 14, 2016 and is downtrending. It has underperformed by 81.43% the S&P500.

According to Zacks Investment Research, “TetraLogic Pharmaceuticals Corporation is a biopharmaceutical company primarily in the United States. The company focuses on the discovery and development of Smac mimetics, small molecule peptide mimetics that mimic Smac for the treatment of cancers. TetraLogic Pharmaceuticals Corporation is headquartered in Malvern, Pennsylvania.”

Bank Of New York Mellon Corp holds 0% of its portfolio in Tetralogic Pharmaceuticals Corp for 13,968 shares. Blackrock Fund Advisors owns 1,931 shares or 0% of their US portfolio. Moreover, Burt Wealth Advisors has 0% invested in the company for 2,625 shares. The California-based California Public Employees Retirement System has invested 0% in the stock. Creative Planning, a Kansas-based fund reported 12,102 shares.#img1#

TLOG Company Profile

TetraLogic Pharmaceuticals Corporation, incorporated on October 22, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Firm has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Firm is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease resulting in the loss of hair on the scalp and elsewhere on the body. SHAPE has been granted the United States orphan drug designation for CTCL. SHAPE is a therapeutic designed to maximize HDAC inhibition locally in the skin with limited systemic exposure. The Firm is conducting Phase II clinical trial of SHAPE.

More news for Tetralogic Pharmaceuticals Corp (OTCMKTS:TLOG) were recently published by: Marketwatch.com, which released: “TetraLogic Pharmaceuticals Corp.” on August 19, 2011. Quotes.Wsj.com‘s article titled: “News TetraLogic Pharmaceuticals Corp.TLOG” and published on November 24, 2013 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Nellie Frank


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>